Orders from 1390 SEK Free delivery from 2895 SEK Ready for pickup dead drop: collect in 5 min Free parcel delivery from 2895 SEK

Substances · Cannabinoids (Indazole carboxamides)

4F-MDMB-BINACA

C19H26FN3O3 CAS 2390036-46-9 Analytical reference material — not for human consumption
4F-MDMB-BINACA, educational illustration of the molecular structure
Educational illustration of the molecular structure. This is not a photograph of the product.
Preferred name
4F-MDMB-BINACA
IUPAC name
methyl (2S)-2-[[1-(4-fluorobutyl)indazole-3-carbonyl]amino]-3,3-dimethylbutanoate
Parent CAS number (reference)
2390036-46-9
Molecular formula
C19H26FN3O3
Molecular weight
363.4 g/mol
InChIKey
GZGKSDAMWRWYOZ-MRXNPFEDSA-N
PubChem
CID 145707216
Source
PubChem
Verified synonyms & catalog abbreviations
4F-MDMB-BUTINACA 4-Fluoro-MDMB-BINACA 4F-ADB 4FMDMBBINACA 4F MDMB BINACA

Verified Neurochemical & Toxicological Intelligence

4F-MDMB-BINACA (4F-MDMB-BUTINACA)

Synthetic Cannabinoid Receptor Agonist (Low-Nanomolar CB1 Agonist) Indazole-3-carboxamide (4-fluorobutyl tert-leucinate methyl ester)
Verified PubChem & CAS Identity C19H26FN3O3 · CAS 2390036-46-9 · CID 145707216
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 363.43 g/mol
Peer-Reviewed & Agency Citations 3 · verified sources

Receptor Telemetry & Mechanism of Action

CB₁ Cannabinoid CB₁ Receptor 0.2 nM

Potent indazole-3-carboxamide CB1 agonist shortening 5F-MDMB-PINACA's 5-fluoropentyl tail by one carbon to a 4-fluorobutyl chain (C19H26FN3O3 — distinct from pentyl isomer 4F-MDMB-PINACA and indole 4F-MDMB-BICA). In WHO 42nd ECDD GTPgammaS assays, 4F-MDMB-BINACA activated human CB1 at EC50 = 0.20 nM (Emax = 67.7% vs. CP-55,940; ~71-fold more potent than Delta9-THC at EC50 = 14.2 nM), while beta-arrestin assays report EC50 = 5.69–7.39 nM. Repeated oral administration in rats also induced considerable liver, kidney, and metabolic toxicity.

Biotransformation & Active Metabolites

Biotransformed via methyl ester cleavage, hydrolytic defluorination, oxidation to a butanoic acid metabolite, N-dealkylation, dehydrogenation, and aromatic/alkyl hydroxylation.

Temporal Pharmacokinetics

Fast-hitting, heavy cannabimimetic sedation, perceptual warping, and mood elevation at low microgram levels, escalating sharply into confusion, ataxia, tachycardia, vomiting, and stupor if over-titrated.

  1. Onset 1–3 minutes inhaled
  2. Peak Window 10–30 minutes inhaled
  3. Total Window 1–2.5 hours inhaled (class estimate; WHO 42nd ECDD notes exact human duration is unestablished)
  4. Residual / Half-Life 1–4 hours of residual somnolence and cognitive fog; human plasma half-life is unverified.

MICROGRAM POTENCY HAZARD: Roughly ~4-fold higher in beta-arrestin EC50 than 5F-MDMB-PINACA yet still ~71 times more potent than THC in GTPgammaS binding and prominently identified in post-mortem forensic casework. Active exposures sit in the estimated 60–250 ug range; unweighed 1 mg powder grains risk abrupt unconsciousness, seizures, and fatal toxicity.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
30–60 ug (0.03–0.06 mg — tentative microgram estimate)
Cognitive & Sensory

Subtle sensory softening, mild mood lift, and early relaxation.

Somatic & Autonomic

Slight ocular warmth and faint dry mouth.

Light
60–120 ug (0.06–0.12 mg — tentative microgram estimate)
Cognitive & Sensory

Calm cannabimimetic mood elevation, brightened music/sensory perception, and slowed thought pace.

Somatic & Autonomic

Dry mouth, red eyes, gentle muscle heaviness, and mild pulse increase.

Common Reference
120–250 ug (0.12–0.25 mg — tentative microgram estimate)
Cognitive & Sensory

Pronounced heavy stone, time dilation, short-term memory impairment, and dreamy detachment.

Somatic & Autonomic

Marked sedation, impaired motor coordination, tachycardia, dizziness, and appetite stimulation.

Strong
250–400 ug (0.25–0.40 mg — tentative microgram estimate)
Cognitive & Sensory

Severe confusion, dissociative vertigo, acute anxiety/paranoia, and memory blackouts.

Somatic & Autonomic

Strong ataxia, orthostatic hypotension, nausea/emesis, tremors, and palpitations.

Heavy / Toxic Zone
400–500+ ug (0.40–0.50+ mg — tentative microgram estimate)
Cognitive & Sensory

Coma / sudden loss of consciousness, agitated delirium, and acute psychosis.

Somatic & Autonomic

Severe vomiting with aspiration risk, convulsions, respiratory depression, hepatorenal stress, and fatal intoxication.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Alcohol, Opioids, Benzodiazepines, and GHB/GBL

Synergistic CNS depression, loss of gag reflex during vomiting, and fatal respiratory arrest.

Other Synthetic Cannabinoids (co-detected with 5F-MDMB-PICA in 41% of forensic cases)

Compounds CB1 overactivation; 69% of a 29-case US forensic series involving 4F-MDMB-BINACA originated from post-mortem investigations.

Stimulants / Cathinones and Lithium

Precipitates severe tachycardia, arrhythmias, psychotic delirium, and convulsions.

Elevated Hazard — Avoid

Psychedelics, Dissociatives, and Tramadol

Heightens seizure risk, severe confusion, and terrifying panic states.

Hepatotoxic or Nephrotoxic agents

Preclinical rat studies demonstrate considerable toxic effects on liver, kidney, and metabolic functions after 1-week oral exposure.

Caution / Receptor Attenuation

Botanical Cannabis

Never mix onto plant material—eliminates THC's partial-agonist safety margin.

Structural Isomer & Sibling Comparison

4F-MDMB-BINACA (4-fluorobutyl tail, C19H26FN3O3) is one methylene unit shorter than 5F-MDMB-PINACA (5-fluoropentyl tail, C20H28FN3O3). That 1-carbon shortening lowers beta-arrestin recruitment potency ~4-fold (EC50 5.69–7.39 nM vs. 0.84–1.78 nM for 5F-ADB), aligning 4F-MDMB-BINACA closely with MDMB-4en-PINACA and ADB-BUTINACA while remaining ~71x more potent than botanical THC in GTPgammaS assays.

Physicochemical Stability & Storage

Physical Form: White or off-white neat solid or crystalline powder (NEVER supplied on sprayed herbs). · Soluble in DMF, ethanol, dichloromethane, and methanol; partially soluble in water.

Store sealed, dry, and protected from light at -20 °C or cool room temperature.

Cross-Tolerance & Dependence Profile

Rapid CB1 receptor tolerance and physical dependence with repeated use; full cross-tolerance across all synthetic and botanical cannabinoids.

Codes on this card

Short meanings for the abbreviations printed with this substance.

Open the full glossary →
CB₁ / CB₂ Cannabinoid receptors CB1 and CB2

CB1 and CB2 are the two cannabinoid receptors named on these cards. Papers usually discuss CB1 in the nervous system and CB2 more often in immune tissue. The number beside them is often a Ki in nanomoles.

EC₅₀ / IC₅₀ Halfway concentration

EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.

Kᵢ Binding tightness in nanomoles

Ki says how tightly a compound sits on a receptor in a binding test. It is written in nanomoles per litre. A Ki of 1 nM means very tight binding in that experiment.

ratio Selectivity ratio

A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.

curve Concentration-response curve

The response curve plots concentration along the bottom and the measured laboratory response up the side. It is usually flat, then steep, then flat again near the top. EC50 sits on the steep middle.

CAS CAS registry number

A CAS number is a passport number for one chemical entry in the CAS registry. The free base and a salt of the same parent usually have different CAS numbers.

IUPAC IUPAC Name & Molecular Formula

The molecular formula counts how many atoms of each element sit in one molecule, while the IUPAC name is the systematic map showing exactly how those atoms are connected.

CID / InChIKey PubChem CID & Standard InChIKey

PubChem CID is the catalog number in the U.S. National Library of Medicine chemistry database, and InChIKey is a 27-character digital fingerprint of the molecule's exact 3D structure.

Comprehensive Analytical & Toxicological Monograph

4F-MDMB-BINACA (4F-MDMB-BUTINACA; methyl (2S)-2-[1-(4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate; CAS 2390036-46-9, PubChem CID 145707216) is a fluorinated indazole-3-carboxamide supplied strictly as a pure analytical solid or crystalline powder (`pure_powder_or_crystal`, C19H26FN3O3, 363.43 g/mol — never as sprayed herbs). Structurally, it is the four-carbon 4-fluorobutyl homologue of 5F-MDMB-PINACA (and distinct from five-carbon isomer 4F-MDMB-PINACA). In WHO 42nd ECDD and peer-reviewed receptor studies, 4F-MDMB-BINACA activates human CB1 receptors at low nanomolar concentrations (GTPgammaS EC50 = 0.20 nM vs. 14.2 nM for Delta9-THC; beta-arrestin EC50 = 5.69–7.39 nM), operating ~71 times more potently than natural THC. Because reliable clinical human quantitative brackets data do not exist, tentative microgram harm-reduction brackets place inhaled threshold effects around 30–60 ug, light relaxation at 60–120 ug, common heavy cannabimimetic stone at 120–250 ug, strong confusion and ataxia at 250–400 ug, and life-threatening overdose (unconsciousness, vomiting aspiration, seizures) above 400–500 ug (0.4–0.5 mg). Unweighed 'eyeballing' of pure powder is potentially fatal; volumetric liquid dilution is mandatory for microgram accuracy. Inhaled effects begin within minutes across an estimated 1–2.5 hour window. Compared to 5F-MDMB-PINACA and ADB-PINACA, 4F-MDMB-BINACA is ~4-fold less extreme in beta-arrestin potency and aligns closely with MDMB-4en-PINACA and ADB-BUTINACA, though subacute rat toxicology flags significant liver and kidney strain with repeated intake. Never combine with alcohol, opioids, benzodiazepines, GHB/GBL, other synthetic cannabinoids, stimulants, or lithium.

Chemical Architecture & Structural Profile

4F-MDMB-BINACA (methyl (2S)-2-[[1-(4-fluorobutyl)indazole-3-carbonyl]amino]-3,3-dimethylbutanoate) is a reference compound belonging to the Cannabinoids (Indazole carboxamides) class, characterized by the molecular formula C19H26FN3O3 and a molar mass of 363.4 g/mol. The parent molecule is indexed under CAS registry number 2390036-46-9 and in the NCBI PubChem database as CID 145707216 (Standard InChIKey: GZGKSDAMWRWYOZ-MRXNPFEDSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), 4F-MDMB-BINACA is indexed within the Cannabinoids (Indazole carboxamides) structural group. Synthetic indazole carboxamide exhibiting high receptor affinity in in-vitro assays; requires calibrated micro-analytical balances and full dermal and respiratory protection. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations